FDA Approves Rybrevant Faspro for the Treatment of EGFR Mutated Non Small Cell Lung Cancer Offering a New Option in Targeted Therapy

On December 17, 2025, the United States Food and Drug Administration granted approval for Rybrevant Faspro, a co-formulation of amivantamab and hyaluronidase-lpuj, for the treatment of patients with non small cell lung cancer that harbors epidermal growth factor receptor mutations. This approval represents an important milestone in the management of EGFR mutated NSCLC, providing a treatment option that combines effectiveness with improved patient convenience and tolerability.

Rybrevant Faspro is an innovative therapy designed to simplify administration and improve the overall treatment experience for patients. Traditional intravenous infusions of targeted therapies such as amivantamab require hours in a clinical setting and can sometimes result in infusion related reactions that are uncomfortable and time consuming. By contrast, the subcutaneous formulation of Rybrevant Faspro allows the drug to be administered in about five minutes. This significant reduction in treatment time not only decreases the burden on patients but also improves clinic efficiency. Patients can now receive the therapy in a short outpatient visit rather than spending hours attached to an IV. This development aligns with a broader movement in oncology to make treatments less disruptive to patients’ lives while maintaining clinical effectiveness.

The components of Rybrevant Faspro work together to achieve these outcomes. Amivantamab is a bispecific antibody that targets both EGFR and MET. These molecules are key drivers of tumor growth in certain lung cancers, and targeting them helps to block cancer cell proliferation while engaging the immune system to attack cancer cells. Hyaluronidase-lpuj is an enzyme that temporarily loosens connective tissue under the skin, allowing the antibody to be absorbed efficiently when administered subcutaneously. This co-formulation ensures that the therapeutic benefits of amivantamab are maintained while simplifying the delivery process.

Patients who are eligible for Rybrevant Faspro are adults with advanced or metastatic non small cell lung cancer with specific EGFR mutations. The therapy can be used in several treatment scenarios. It may be combined with the EGFR tyrosine kinase inhibitor lazertinib for first-line treatment of locally advanced or metastatic disease. It can also be used with chemotherapy for patients whose disease has progressed after prior treatments. In some cases, Rybrevant Faspro may be used as a single agent for patients who have already received platinum-based chemotherapy. This flexibility reflects the drug’s established role in the treatment of EGFR mutated NSCLC and extends it to the more convenient subcutaneous formulation.

The FDA’s approval of Rybrevant Faspro was supported by clinical data demonstrating that the subcutaneous formulation delivers comparable pharmacokinetics and clinical effectiveness to the intravenous form. The Phase 3 PALOMA-3 study showed that patients receiving the subcutaneous injection experienced fewer administration-related reactions and tolerated therapy well. These results suggest that subcutaneous delivery maintains the efficacy of the intravenous drug while improving safety and convenience. This is an important consideration for patients who already face the physical and emotional challenges of living with lung cancer.

Non small cell lung cancer accounts for approximately 85 percent of all lung cancers and remains a leading cause of cancer-related death worldwide. EGFR mutations are among the most frequent drivers of tumor growth in NSCLC, making targeted therapies a critical part of modern oncology care. Over the past decade, the introduction of EGFR inhibitors has significantly improved outcomes for patients with these mutations, offering more effective and less toxic alternatives to traditional chemotherapy. Rybrevant Faspro builds on this progress by providing a delivery method that reduces treatment burden while maintaining therapeutic benefits.

The approval of Rybrevant Faspro also highlights a broader trend in cancer care toward patient-centered approaches. Subcutaneous administration reduces the time patients spend in clinics, lowers the risk of infusion-related side effects, and increases overall convenience. This can improve adherence to treatment regimens and enhance the quality of life for patients undergoing long-term therapy. In addition, the reduced time and resource requirements for administration may help clinics manage high patient volumes more efficiently, ultimately expanding access to advanced therapies for more patients.

While Rybrevant Faspro does not change the underlying mechanism of action of amivantamab, it represents a meaningful innovation in how therapy is delivered. For many patients with EGFR mutated NSCLC, this change will make treatment more manageable and less disruptive. The approval is an important example of how advances in drug formulation can complement breakthroughs in targeted therapy to improve patient experience.

The combination of amivantamab and hyaluronidase-lpuj in Rybrevant Faspro reflects a thoughtful approach to improving cancer care. By targeting key pathways in tumor growth and ensuring rapid and efficient absorption of the therapeutic antibody, this formulation addresses both the biological and practical challenges faced by patients and clinicians. The approval of Rybrevant Faspro offers hope for patients who require effective therapy but seek options that fit more easily into their daily lives.

Healthcare providers should discuss the potential benefits and risks of Rybrevant Faspro with their patients. Individual treatment decisions depend on specific disease characteristics, prior therapies, and overall health status. As with any cancer therapy, monitoring for side effects and response to treatment is essential to ensure optimal outcomes. Patients and caregivers should work closely with their oncology team to determine whether Rybrevant Faspro is an appropriate choice within their treatment plan.

Looking ahead, the introduction of subcutaneous formulations like Rybrevant Faspro may inspire further innovation in the delivery of targeted therapies for other types of cancer. Making treatments faster, safer, and more convenient aligns with the goals of precision medicine, which aims to provide the right therapy to the right patient while minimizing disruption to their lives. By reducing treatment time and side effects, subcutaneous administration represents an important step in enhancing patient-centered care in oncology.

In summary, the FDA’s approval of Rybrevant Faspro for the treatment of EGFR mutated non small cell lung cancer is a significant development for patients, clinicians, and the broader oncology community. The combination of amivantamab and hyaluronidase-lpuj provides an effective targeted therapy that is easier to administer, better tolerated, and more convenient than traditional intravenous therapy. This approval represents a meaningful advance in the management of NSCLC and reinforces the importance of developing therapies that address both clinical efficacy and patient experience.

For patients with advanced or metastatic NSCLC and EGFR mutations, Rybrevant Faspro offers a promising new option. The therapy exemplifies the progress made in targeted oncology and the growing emphasis on patient-centered care. As more patients gain access to this treatment, it has the potential to improve both clinical outcomes and quality of life.

Patients or caregivers interested in learning more about Rybrevant Faspro should consult their oncology team to discuss eligibility and treatment planning. The approval of this therapy represents a step forward in making high-quality cancer care more accessible, convenient, and effective for those who need it most.